Can-Fite BioPharma Ltd (CANF):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Can-Fite BioPharma Ltd (CANF) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C3455)・商品コード:DATA904C3455
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:55
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Can-Fite BioPharma Ltd (Can-Fite) is a biopharmaceutical company that offers pharmaceutical discovery and clinical development services. The company’s pipeline product portfolio includes CF101, CF102 and CF602. It develops its products by utilizing its platform technology based on the Gi protein coupled A3 adenosine receptor (A3AR) in inflammatory and cancer cells. Can-Fite developes drugs that are used in the treatment of various diseases such as cancer, sexual dysfunction, inflammatory diseases and ophthalmic indications. The company’s CF 102, is an oral drug used to treat liver cancer and CF 602, is an allosteric modulator used in the treatment of inflammatory diseases. It conducts Phase I, II and III clinical trials for various indications across the US and Israel. Can-Fite is headquartered in Petah-Tikva, Israel.

Can-Fite BioPharma Ltd (CANF) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Can-Fite BioPharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Can-Fite BioPharma Enters into Distribution Agreement with Gebro Pharma 13
Can-Fite BioPharma Enters into Research Agreement with Hadassah Medical Center 14
Can-Fite BioPharma Enters into Distribution Agreement with Chong Kun Dang Pharma 15
Can-Fite BioPharma To Enter Into Co-Development Agreement With Smart Assays BioTech 16
Merger 17
OphthaliX Merges with Wize Pharma 17
Licensing Agreements 18
CMS Medical Enters into Licensing Agreement with Can-Fite BioPharma 18
Wize Pharma Amends Licensing Agreement with Resdevco 19
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 21
Equity Offering 22
Can-Fite BioPharma to Raise USD5 Million in Private Placement of American Depositary Shares 22
Wize Pharma Files Registration Statement for Public Offering of Shares for up to USD7.5 Million 23
Can-Fite BioPharma Plans to Raise USD50 Million in Public Offering of Securities 24
Wize Pharma Raises USD1 Million in Private Placement of Shares 25
Can-Fite Biopharma Files Registration Statement for Public Offering of Shares for up to USD5 Million 26
Can-Fite BioPharma Raises USD5 Million in Private Placement of ADSs 27
Can-Fite BioPharma Raises USD4.8 Million in Private Placement of Shares 28
Can-Fite BioPharma Raises USD9 Million in Private Placement of American Depository Shares 29
Can-Fite BioPharma Raises USD8 Million in Private Placement of American Depositary Shares 30
Can-Fite BioPharma Completes Private Placement Of American Depositary Shares For US$5 Million 32
Can-Fite BioPharma Completes Public Offering Of Units For US$6 Million 33
OphthaliX Withdraws Public Offering of Shares for USD10 Million 34
Can-Fite BioPharma Completes Public Offering Of Units For US$7.2 Million 35
Can-Fite BioPharma Ltd – Key Competitors 36
Can-Fite BioPharma Ltd – Key Employees 37
Can-Fite BioPharma Ltd – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Strategy And Business Planning 39
Jan 11, 2018: Can-Fite 12 Months’ Activities & Milestones for 2018 39
Financial Announcements 40
Jun 01, 2018: Can-Fite Reports First Quarter 2018 Financial Results and Provides Clinical Update 40
Mar 23, 2018: Can-Fite BioPharma Announces Reports 2017 Financial Results 42
Nov 27, 2017: Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update 44
Sep 01, 2017: Can-Fite Reports Second Quarter 2017 Financial Results & Provides Clinical Update 47
May 30, 2017: Can-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update 49
Mar 31, 2017: Can-Fite Reports 2016 Financial Results & Provides Clinical Update 51
Research And Development 53
Jun 05, 2017: Can-Fite BioPharma establishes clinical advisory board for NAFLD and NASH treatment 53
Other Significant Developments 54
Jan 11, 2018: Can-Fite 12 Months’ Activities & Milestones for 2018 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Can-Fite BioPharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Can-Fite BioPharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Can-Fite BioPharma Enters into Distribution Agreement with Gebro Pharma 13
Can-Fite BioPharma Enters into Research Agreement with Hadassah Medical Center 14
Can-Fite BioPharma Enters into Distribution Agreement with Chong Kun Dang Pharma 15
Can-Fite BioPharma To Enter Into Co-Development Agreement With Smart Assays BioTech 16
OphthaliX Merges with Wize Pharma 17
CMS Medical Enters into Licensing Agreement with Can-Fite BioPharma 18
Wize Pharma Amends Licensing Agreement with Resdevco 19
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 21
Can-Fite BioPharma to Raise USD5 Million in Private Placement of American Depositary Shares 22
Wize Pharma Files Registration Statement for Public Offering of Shares for up to USD7.5 Million 23
Can-Fite BioPharma Plans to Raise USD50 Million in Public Offering of Securities 24
Wize Pharma Raises USD1 Million in Private Placement of Shares 25
Can-Fite Biopharma Files Registration Statement for Public Offering of Shares for up to USD5 Million 26
Can-Fite BioPharma Raises USD5 Million in Private Placement of ADSs 27
Can-Fite BioPharma Raises USD4.8 Million in Private Placement of Shares 28
Can-Fite BioPharma Raises USD9 Million in Private Placement of American Depository Shares 29
Can-Fite BioPharma Raises USD8 Million in Private Placement of American Depositary Shares 30
Can-Fite BioPharma Completes Private Placement Of American Depositary Shares For US$5 Million 32
Can-Fite BioPharma Completes Public Offering Of Units For US$6 Million 33
OphthaliX Withdraws Public Offering of Shares for USD10 Million 34
Can-Fite BioPharma Completes Public Offering Of Units For US$7.2 Million 35
Can-Fite BioPharma Ltd, Key Competitors 36
Can-Fite BioPharma Ltd, Key Employees 37
Can-Fite BioPharma Ltd, Other Locations 38
Can-Fite BioPharma Ltd, Subsidiaries 38

List of Figures
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Can-Fite BioPharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Can-Fite BioPharma Ltd (CANF):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C3455)販売に関する免責事項を必ずご確認ください。
★調査レポート[Can-Fite BioPharma Ltd (CANF):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆